Intrinsic value of Hologic - HOLX

Previous Close

$37.42

  Intrinsic Value

$16.08

stock screener

  Rating & Target

str. sell

-57%

  Value-price divergence*

-60%

Previous close

$37.42

 
Intrinsic value

$16.08

 
Up/down potential

-57%

 
Rating

str. sell

 
Value-price divergence*

-60%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of HOLX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 10.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  4.73
  4.70
  4.73
  4.76
  4.78
  4.80
  4.82
  4.84
  4.86
  4.87
  4.88
  4.90
  4.91
  4.92
  4.92
  4.93
  4.94
  4.94
  4.95
  4.95
  4.96
  4.96
  4.97
  4.97
  4.97
  4.98
  4.98
  4.98
  4.98
  4.98
  4.99
Revenue, $m
  2,833
  2,966
  3,106
  3,254
  3,410
  3,574
  3,746
  3,927
  4,118
  4,319
  4,529
  4,751
  4,984
  5,229
  5,487
  5,757
  6,042
  6,340
  6,654
  6,984
  7,330
  7,694
  8,076
  8,478
  8,899
  9,342
  9,807
  10,296
  10,809
  11,348
  11,913
Variable operating expenses, $m
 
  2,523
  2,629
  2,741
  2,858
  2,982
  3,112
  3,250
  3,394
  3,545
  3,705
  3,592
  3,768
  3,954
  4,148
  4,353
  4,568
  4,794
  5,031
  5,280
  5,542
  5,817
  6,106
  6,410
  6,728
  7,063
  7,415
  7,784
  8,172
  8,579
  9,007
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,289
  2,523
  2,629
  2,741
  2,858
  2,982
  3,112
  3,250
  3,394
  3,545
  3,705
  3,592
  3,768
  3,954
  4,148
  4,353
  4,568
  4,794
  5,031
  5,280
  5,542
  5,817
  6,106
  6,410
  6,728
  7,063
  7,415
  7,784
  8,172
  8,579
  9,007
Operating income, $m
  543
  443
  477
  514
  551
  591
  633
  678
  724
  773
  825
  1,159
  1,216
  1,276
  1,338
  1,404
  1,474
  1,547
  1,623
  1,704
  1,788
  1,877
  1,970
  2,068
  2,171
  2,279
  2,392
  2,512
  2,637
  2,768
  2,906
EBITDA, $m
  1,008
  987
  1,033
  1,082
  1,134
  1,189
  1,246
  1,306
  1,370
  1,437
  1,507
  1,580
  1,658
  1,739
  1,825
  1,915
  2,010
  2,109
  2,213
  2,323
  2,438
  2,559
  2,687
  2,820
  2,960
  3,108
  3,262
  3,425
  3,595
  3,775
  3,963
Interest expense (income), $m
  185
  162
  174
  186
  200
  214
  229
  245
  261
  279
  297
  316
  336
  358
  380
  403
  428
  454
  481
  510
  540
  572
  605
  640
  676
  715
  755
  797
  842
  889
  938
Earnings before tax, $m
  415
  282
  304
  327
  352
  377
  405
  433
  463
  495
  528
  843
  880
  918
  958
  1,001
  1,046
  1,093
  1,142
  1,194
  1,248
  1,305
  1,365
  1,428
  1,495
  1,564
  1,637
  1,714
  1,795
  1,879
  1,968
Tax expense, $m
  84
  76
  82
  88
  95
  102
  109
  117
  125
  134
  142
  228
  237
  248
  259
  270
  282
  295
  308
  322
  337
  352
  369
  386
  404
  422
  442
  463
  485
  507
  531
Net income, $m
  331
  206
  222
  239
  257
  276
  295
  316
  338
  361
  385
  615
  642
  670
  700
  731
  763
  798
  834
  871
  911
  953
  997
  1,043
  1,091
  1,142
  1,195
  1,251
  1,310
  1,372
  1,437

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  548
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  7,317
  7,079
  7,414
  7,767
  8,138
  8,529
  8,940
  9,373
  9,828
  10,307
  10,810
  11,339
  11,896
  12,480
  13,095
  13,741
  14,419
  15,132
  15,881
  16,668
  17,495
  18,363
  19,275
  20,233
  21,240
  22,297
  23,407
  24,572
  25,797
  27,083
  28,433
Adjusted assets (=assets-cash), $m
  6,769
  7,079
  7,414
  7,767
  8,138
  8,529
  8,940
  9,373
  9,828
  10,307
  10,810
  11,339
  11,896
  12,480
  13,095
  13,741
  14,419
  15,132
  15,881
  16,668
  17,495
  18,363
  19,275
  20,233
  21,240
  22,297
  23,407
  24,572
  25,797
  27,083
  28,433
Revenue / Adjusted assets
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
  0.419
Average production assets, $m
  3,292
  3,447
  3,610
  3,781
  3,962
  4,153
  4,353
  4,563
  4,785
  5,018
  5,263
  5,521
  5,792
  6,076
  6,376
  6,690
  7,020
  7,368
  7,732
  8,115
  8,518
  8,941
  9,385
  9,851
  10,341
  10,856
  11,396
  11,964
  12,560
  13,186
  13,843
Working capital, $m
  425
  181
  189
  199
  208
  218
  229
  240
  251
  263
  276
  290
  304
  319
  335
  351
  369
  387
  406
  426
  447
  469
  493
  517
  543
  570
  598
  628
  659
  692
  727
Total debt, $m
  3,345
  3,275
  3,516
  3,771
  4,038
  4,320
  4,617
  4,929
  5,257
  5,602
  5,965
  6,347
  6,748
  7,169
  7,612
  8,078
  8,567
  9,081
  9,621
  10,189
  10,785
  11,411
  12,068
  12,759
  13,485
  14,247
  15,047
  15,888
  16,770
  17,697
  18,671
Total liabilities, $m
  5,174
  5,104
  5,345
  5,600
  5,867
  6,149
  6,446
  6,758
  7,086
  7,431
  7,794
  8,176
  8,577
  8,998
  9,441
  9,907
  10,396
  10,910
  11,450
  12,018
  12,614
  13,240
  13,897
  14,588
  15,314
  16,076
  16,876
  17,717
  18,599
  19,526
  20,500
Total equity, $m
  2,143
  1,975
  2,068
  2,167
  2,270
  2,380
  2,494
  2,615
  2,742
  2,876
  3,016
  3,164
  3,319
  3,482
  3,653
  3,834
  4,023
  4,222
  4,431
  4,650
  4,881
  5,123
  5,378
  5,645
  5,926
  6,221
  6,530
  6,856
  7,197
  7,556
  7,933
Total liabilities and equity, $m
  7,317
  7,079
  7,413
  7,767
  8,137
  8,529
  8,940
  9,373
  9,828
  10,307
  10,810
  11,340
  11,896
  12,480
  13,094
  13,741
  14,419
  15,132
  15,881
  16,668
  17,495
  18,363
  19,275
  20,233
  21,240
  22,297
  23,406
  24,573
  25,796
  27,082
  28,433
Debt-to-equity ratio
  1.561
  1.660
  1.700
  1.740
  1.780
  1.820
  1.850
  1.880
  1.920
  1.950
  1.980
  2.010
  2.030
  2.060
  2.080
  2.110
  2.130
  2.150
  2.170
  2.190
  2.210
  2.230
  2.240
  2.260
  2.280
  2.290
  2.300
  2.320
  2.330
  2.340
  2.350
Adjusted equity ratio
  0.236
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279
  0.279

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  331
  206
  222
  239
  257
  276
  295
  316
  338
  361
  385
  615
  642
  670
  700
  731
  763
  798
  834
  871
  911
  953
  997
  1,043
  1,091
  1,142
  1,195
  1,251
  1,310
  1,372
  1,437
Depreciation, amort., depletion, $m
  465
  543
  556
  569
  583
  597
  613
  629
  646
  663
  682
  421
  442
  464
  487
  511
  536
  562
  590
  619
  650
  682
  716
  752
  789
  829
  870
  913
  959
  1,007
  1,057
Funds from operations, $m
  843
  749
  778
  808
  839
  873
  908
  945
  984
  1,024
  1,067
  1,037
  1,084
  1,134
  1,186
  1,241
  1,299
  1,360
  1,424
  1,491
  1,561
  1,635
  1,713
  1,795
  1,881
  1,971
  2,065
  2,165
  2,269
  2,378
  2,494
Change in working capital, $m
  56
  8
  9
  9
  9
  10
  11
  11
  12
  12
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  26
  27
  28
  30
  31
  33
  35
Cash from operations, $m
  787
  741
  769
  799
  830
  863
  897
  934
  972
  1,012
  1,054
  1,023
  1,070
  1,119
  1,171
  1,225
  1,282
  1,342
  1,405
  1,471
  1,540
  1,613
  1,690
  1,770
  1,855
  1,944
  2,037
  2,135
  2,238
  2,346
  2,459
Maintenance CAPEX, $m
  0
  -251
  -263
  -276
  -289
  -302
  -317
  -332
  -348
  -365
  -383
  -402
  -421
  -442
  -464
  -487
  -511
  -536
  -562
  -590
  -619
  -650
  -682
  -716
  -752
  -789
  -829
  -870
  -913
  -959
  -1,007
New CAPEX, $m
  -99
  -155
  -163
  -172
  -181
  -190
  -200
  -211
  -222
  -233
  -245
  -258
  -271
  -285
  -299
  -314
  -330
  -347
  -365
  -383
  -402
  -423
  -444
  -466
  -490
  -515
  -540
  -568
  -596
  -626
  -657
Cash from investing activities, $m
  -68
  -406
  -426
  -448
  -470
  -492
  -517
  -543
  -570
  -598
  -628
  -660
  -692
  -727
  -763
  -801
  -841
  -883
  -927
  -973
  -1,021
  -1,073
  -1,126
  -1,182
  -1,242
  -1,304
  -1,369
  -1,438
  -1,509
  -1,585
  -1,664
Free cash flow, $m
  719
  335
  343
  352
  361
  370
  380
  391
  402
  414
  426
  364
  378
  392
  408
  424
  441
  459
  478
  497
  518
  540
  563
  587
  613
  640
  668
  697
  728
  761
  795
Issuance/(repayment) of debt, $m
  -443
  226
  241
  254
  268
  282
  297
  312
  328
  345
  363
  382
  401
  422
  443
  466
  489
  514
  540
  567
  596
  626
  658
  691
  726
  762
  800
  841
  883
  927
  974
Issuance/(repurchase) of shares, $m
  -212
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -660
  226
  241
  254
  268
  282
  297
  312
  328
  345
  363
  382
  401
  422
  443
  466
  489
  514
  540
  567
  596
  626
  658
  691
  726
  762
  800
  841
  883
  927
  974
Total cash flow (excl. dividends), $m
  57
  561
  584
  606
  628
  652
  677
  703
  730
  759
  789
  745
  779
  814
  851
  889
  930
  973
  1,018
  1,065
  1,114
  1,166
  1,221
  1,278
  1,338
  1,402
  1,468
  1,538
  1,611
  1,688
  1,769
Retained Cash Flow (-), $m
  -64
  -84
  -93
  -98
  -104
  -109
  -115
  -121
  -127
  -134
  -140
  -148
  -155
  -163
  -171
  -180
  -189
  -199
  -209
  -220
  -231
  -242
  -254
  -267
  -281
  -295
  -310
  -325
  -342
  -359
  -377
Prev. year cash balance distribution, $m
 
  252
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  729
  491
  507
  525
  543
  562
  582
  603
  625
  649
  598
  624
  651
  679
  709
  741
  774
  809
  845
  884
  924
  966
  1,011
  1,058
  1,107
  1,158
  1,212
  1,269
  1,329
  1,392
Discount rate, %
 
  7.60
  7.98
  8.38
  8.80
  9.24
  9.70
  10.18
  10.69
  11.23
  11.79
  12.38
  13.00
  13.65
  14.33
  15.05
  15.80
  16.59
  17.42
  18.29
  19.20
  20.17
  21.17
  22.23
  23.34
  24.51
  25.74
  27.02
  28.37
  29.79
  31.28
PV of cash for distribution, $m
 
  677
  421
  399
  374
  349
  322
  295
  268
  240
  213
  166
  144
  123
  104
  87
  71
  57
  45
  35
  26
  20
  14
  10
  7
  5
  3
  2
  1
  1
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test. The Breast Health segment offers breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. This segment also provides Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View that provides a 2D image; Selenia digital mammography platform; and SecurView Workstation. The GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

FINANCIAL RATIOS  of  Hologic (HOLX)

Valuation Ratios
P/E Ratio 31.4
Price to Sales 3.7
Price to Book 4.8
Price to Tangible Book
Price to Cash Flow 13.2
Price to Free Cash Flow 15.1
Growth Rates
Sales Growth Rate 4.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 11.2%
Cap. Spend. - 3 Yr. Gr. Rate 1.9%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 142.3%
Total Debt to Equity 156.1%
Interest Coverage 3
Management Effectiveness
Return On Assets 6.4%
Ret/ On Assets - 3 Yr. Avg. 3.4%
Return On Total Capital 5.9%
Ret/ On T. Cap. - 3 Yr. Avg. 2.8%
Return On Equity 15.7%
Return On Equity - 3 Yr. Avg. 7.6%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 55.2%
Gross Margin - 3 Yr. Avg. 52.5%
EBITDA Margin 37.6%
EBITDA Margin - 3 Yr. Avg. 32.1%
Operating Margin 19.2%
Oper. Margin - 3 Yr. Avg. 14.8%
Pre-Tax Margin 14.6%
Pre-Tax Margin - 3 Yr. Avg. 7.7%
Net Profit Margin 11.7%
Net Profit Margin - 3 Yr. Avg. 5.7%
Effective Tax Rate 20.2%
Eff/ Tax Rate - 3 Yr. Avg. 36.7%
Payout Ratio 0%

HOLX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HOLX stock intrinsic value calculation we used $2833 million for the last fiscal year's total revenue generated by Hologic. The default revenue input number comes from 2016 income statement of Hologic. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HOLX stock valuation model: a) initial revenue growth rate of 4.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.6%, whose default value for HOLX is calculated based on our internal credit rating of Hologic, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Hologic.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HOLX stock the variable cost ratio is equal to 85.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for HOLX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.3% for Hologic.

Corporate tax rate of 27% is the nominal tax rate for Hologic. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HOLX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HOLX are equal to 116.2%.

Life of production assets of 13.1 years is the average useful life of capital assets used in Hologic operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HOLX is equal to 6.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2143 million for Hologic - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 278.466 million for Hologic is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Hologic at the current share price and the inputted number of shares is $10.4 billion.

RELATED COMPANIES Price Int.Val. Rating
GE General Electr 24.55 16.08  sell
TMO Thermo Fisher 172.57 75.59  str.sell
DHR Danaher 80.87 68.69  hold
BDX Becton Dickins 197.69 58.16  str.sell
BSX Boston Scienti 26.89 19.06  sell
COO Cooper 245.05 146.91  sell
DGX Quest Diagnost 104.87 116.11  hold

COMPANY NEWS

▶ Teva and 3D Systems slide while Kellogg and Tesla jump   [Aug-03-17 04:31PM  Associated Press]
▶ Hologic tops Street 3Q forecasts   [Aug-02-17 09:30PM  Associated Press]
▶ ETFs with exposure to Hologic, Inc. : July 24, 2017   [Jul-24-17 04:29PM  Capital Cube]
▶ Inside Abiomeds Profit Margin Expectations for Fiscal 2018   [Jul-21-17 10:40AM  Market Realist]
▶ ETFs with exposure to Hologic, Inc. : July 14, 2017   [Jul-14-17 02:53PM  Capital Cube]
▶ Hologic Looks Good on the Charts   [Jun-27-17 09:37AM  TheStreet.com]
▶ Stocks Close Mixed As Health Care Leads; 2 Medicals Hit Buy Points   [Jun-22-17 04:14PM  Investor's Business Daily]
▶ ETFs with exposure to Hologic, Inc. : June 16, 2017   [Jun-16-17 03:53PM  Capital Cube]
▶ ETFs with exposure to Hologic, Inc. : June 2, 2017   [Jun-02-17 02:12PM  Capital Cube]
▶ Eaton Vance Worldwide Health Sciences Fund Adds 4 Companies   [May-17-17 04:30PM  GuruFocus.com]
▶ Hologic Smashes Fiscal Q2 Sales Views, Beats On Profit By 4 Cents   [May-10-17 04:45PM  Investor's Business Daily]
▶ Hologic tops Street 2Q forecasts   [04:16PM  Associated Press]
Stock chart of HOLX Financial statements of HOLX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.